SCHEMBL3017318

SCHEMBL3017318

Cc1ccc(C)c(Cc2csc(N3CCC(S(=O)(=O)c4cc(C)c(Cl)cc4Cl)CC3)n2)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.35
LMNA P02545 2/20 0.35
TP53 P04637 1/20 0.35
AR P10275 1/20 0.35
CNR1 P21554 2/20 0.35
CNR2 P34972 2/20 0.35
DNM1L O00429 5/20 0.33
CHRM5 P08912 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
EPHX2 P34913 2/20 0.33
ALDH1A1 P00352 1/20 0.32
CYP1A2 P05177 1/20 0.32
POLB P06746 1/20 0.32
CYP2C9 P11712 1/20 0.32
HPGD P15428 1/20 0.32
CYP2C19 P33261 1/20 0.32
HTT P42858 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2998623 0.91 MAPT (0.37) MAPTLMNATP53ARCNR1
SCHEMBL3010811 0.91 EPHX2 (0.37) MAPTLMNATP53ARCNR1
SCHEMBL3008914 0.90 LMNA (0.38) LMNACNR1CNR2DNM1LCHRM5
SCHEMBL3003909 0.89 CTSS (0.40) MAPTLMNATP53ARDNM1L
SCHEMBL3016337 0.89 SMN1; SMN2 (0.36) MAPTLMNACNR1CNR2DNM1L
SCHEMBL3006944 0.89 LMNA (0.34) MAPTLMNATP53ARCNR1
SCHEMBL3019762 0.89 CTSS (0.43) MAPTLMNATP53AREPHX2
SCHEMBL3018584 0.88 EPHX2 (0.42) MAPTLMNAARCNR1CNR2
SCHEMBL3002483 0.88 ALDH1A1 (0.41) MAPTLMNATP53CNR1CNR2
SCHEMBL3020861 0.88 CTSS (0.40) MAPTLMNATP53ARDNM1L

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885LMNA 80/4885TP53 2880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.